Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P210037/S012

Prospera Spinal Cord Stimulation (SCS) System, Resilience Percutaneous Lead, HomeStream Remote Management

Biotronik Nro, Inc. · Decision date May 14, 2026

FDA DECISIONP210037/S012

What did the FDA approve?

FDA records P210037/S012 as a supplement to PMA P210037, with the supplement type “Real-Time Process”. The recorded decision is approval, dated May 14, 2026.

FDA approval order statement

approval of a 20-in length version of the approved Tunnelling Tool (an accessory), with updated packaging, to the Prospera SCS System product family
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Neurology
Decision date
May 14, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P210037/S012
Regulatory pathway
PMA supplement
Product code
LGW
Decision code
APPR
Decision date
May 14, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.

Product code
LGW
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P210037/S012 received

    Application receipt date recorded by FDA.

  2. P210037/S013 · Related supplement

    Prospera SCS System; Resilience Percutaneous Lead; Embrace One; TrueLock

  3. P210037/S015 · Related supplement

    Prospera Spinal Cord Stimulation (SCS) System, Resilience Percutaneous Lead, HomeStream Remote Management

  4. P210037/S012 · FDA decision

    Real-Time Process

  5. P210037/S017 · Related supplement

    Prospera Spinal Cord Stimulation (SCS) System; Resilience Percutaneous Lead; Embrace One; TrueLock

Timeline entries are records held by MedtechLedger for P210037. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P210037

Explore the linked device profile

Other records with product code LGW

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik Nro, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6024 Jean Rd., Lake Oswego, OR, 97035

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records